Figures computed from official regulatory filings — .
Analysttarget 10.5 USD (+973%) · consensus 4.75/5 · 4 buy · 0 hold · 0 sell
Ownershipinsiders 11.79% · institutions 22.22% · short 15.7% of float
In USD · as of Oct 19, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Annovis Bio, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Market information source · Oct 19, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 19, 2026
Open-market timeline · full history
27 buys— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Hoffman Michael Btrack record | Buy | $104.4K | conv 31 |
| Hoffman Michael Btrack record | Buy | $33.9K | conv 31 | SEC |
| Hoffman Michael Btrack record | Buy | $4.5K | conv 30 | SEC |
| Hoffman Michael Btrack record | Buy | $1.5M | conv 63Unusual size | SEC |
| Hoffman Michael Btrack record | Buy | $130.2K | conv 18 | SEC |
| Hoffman Michael Btrack record | Buy | $63.6K | conv 18 | SEC |
| Hoffman Michael Btrack record | Buy | $116.6K | conv 18 | SEC |
| Hoffman Michael Btrack record | Buy | $35.4K | conv 17 | SEC |
| Hoffman Michael Btrack record | Buy | $6.1K | conv 17 | SEC |
| Hoffman Michael Btrack record | Buy | $1.7K | conv 17 | SEC |
| Hoffman Michael Btrack record | Buy | $35K | conv 17 | SEC |
| Hoffman Michael Btrack record | Buy | $34.9K | conv 17 | SEC |
| Hoffman Michael Btrack record | Buy | $31.6K | conv 30 | SEC |
| Bruck Claudine | Exercise | $999.9 | SEC |
| Maccecchini Maria-Luisatrack record | Buy | $200K | conv 48First in 12mo | SEC |
| Hoffman Michael Btrack record | Buy | $2M | conv 55First in 12mo | SEC |
| Bruck Claudine | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Hoffman Michael Btrack record | Award | $11.4K | SEC |
| Hoffman Michael Btrack record | Award | $11.5K | SEC |
| Hoffman Michael Btrack record | Award | $11.5K | SEC |
| Hoffman Michael Btrack record | Award | $17.5K | SEC |
| Hoffman Michael Btrack record | Award | $2.8K | SEC |
| Hoffman Michael Btrack record | Award | $14.3K | SEC |
| Hoffman Michael Btrack record | Award | $13.7K | SEC |
| Walsh Andrew | Award | $1.5K | SEC |